Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin add-on to insulin in T2DM
NCT01306214Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in HbA1c at 18 weeks. Started Feb 2011; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01306214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306214.